GYRE
Price
$9.09
Change
-$0.10 (-1.09%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
854.93M
13 days until earnings call
RVPH
Price
$0.89
Change
+$0.03 (+3.49%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
42.07M
24 days until earnings call
Ad is loading...

GYRE vs RVPH

Header iconGYRE vs RVPH Comparison
Open Charts GYRE vs RVPHBanner chart's image
Gyre Therapeutics
Price$9.09
Change-$0.10 (-1.09%)
Volume$509
Capitalization854.93M
Reviva Pharmaceuticals Holdings
Price$0.89
Change+$0.03 (+3.49%)
Volume$1.6K
Capitalization42.07M
GYRE vs RVPH Comparison Chart
Loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GYRE vs. RVPH commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GYRE is a StrongBuy and RVPH is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (GYRE: $9.19 vs. RVPH: $0.86)
Brand notoriety: GYRE and RVPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GYRE: 60% vs. RVPH: 74%
Market capitalization -- GYRE: $861.49M vs. RVPH: $40.32M
GYRE [@Biotechnology] is valued at $861.49M. RVPH’s [@Biotechnology] market capitalization is $40.32M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GYRE’s FA Score shows that 0 FA rating(s) are green whileRVPH’s FA Score has 1 green FA rating(s).

  • GYRE’s FA Score: 0 green, 5 red.
  • RVPH’s FA Score: 1 green, 4 red.
According to our system of comparison, both GYRE and RVPH are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GYRE’s TA Score shows that 4 TA indicator(s) are bullish while RVPH’s TA Score has 5 bullish TA indicator(s).

  • GYRE’s TA Score: 4 bullish, 4 bearish.
  • RVPH’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, RVPH is a better buy in the short-term than GYRE.

Price Growth

GYRE (@Biotechnology) experienced а +15.74% price change this week, while RVPH (@Biotechnology) price change was +21.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.94%. For the same industry, the average monthly price growth was -5.37%, and the average quarterly price growth was -12.15%.

Reported Earning Dates

GYRE is expected to report earnings on Aug 19, 2025.

RVPH is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+7.94% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GYRE($855M) has a higher market cap than RVPH($42.1M). GYRE YTD gains are higher at: -24.628 vs. RVPH (-50.276). GYRE has higher annual earnings (EBITDA): 11.8M vs. RVPH (-33.27M). GYRE has more cash in the bank: 25.1M vs. RVPH (5.56M). RVPH has less debt than GYRE: RVPH (83K) vs GYRE (1.8M). GYRE has higher revenues than RVPH: GYRE (105M) vs RVPH (0).
GYRERVPHGYRE / RVPH
Capitalization855M42.1M2,031%
EBITDA11.8M-33.27M-35%
Gain YTD-24.628-50.27649%
P/E Ratio182.40N/A-
Revenue105M0-
Total Cash25.1M5.56M452%
Total Debt1.8M83K2,163%
FUNDAMENTALS RATINGS
GYRE vs RVPH: Fundamental Ratings
GYRE
RVPH
OUTLOOK RATING
1..100
197
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
8595
P/E GROWTH RATING
1..100
378
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GYRE's Valuation (89) in the null industry is in the same range as RVPH (93). This means that GYRE’s stock grew similarly to RVPH’s over the last 12 months.

GYRE's Profit vs Risk Rating (78) in the null industry is in the same range as RVPH (100). This means that GYRE’s stock grew similarly to RVPH’s over the last 12 months.

GYRE's SMR Rating (96) in the null industry is in the same range as RVPH (100). This means that GYRE’s stock grew similarly to RVPH’s over the last 12 months.

GYRE's Price Growth Rating (85) in the null industry is in the same range as RVPH (95). This means that GYRE’s stock grew similarly to RVPH’s over the last 12 months.

RVPH's P/E Growth Rating (8) in the null industry is in the same range as GYRE (37). This means that RVPH’s stock grew similarly to GYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GYRERVPH
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 24 days ago
82%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
GYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RVPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARGAX13.080.06
+0.46%
Arbitrage A
MIEZX13.22N/A
N/A
MM S&P 500® Index R5
MUXRX22.78N/A
N/A
Victory S&P 500 Index R
SEQAX15.63N/A
N/A
NAA World Equity Income A
HBLRX14.11N/A
N/A
Hartford Balanced Income R3

GYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GYRE has been loosely correlated with SPRC. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GYRE jumps, then SPRC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GYRE
1D Price
Change %
GYRE100%
-0.76%
SPRC - GYRE
38%
Loosely correlated
+1.71%
SRPT - GYRE
37%
Loosely correlated
+3.82%
BEAM - GYRE
36%
Loosely correlated
+1.51%
RYTM - GYRE
35%
Loosely correlated
+5.23%
PYXS - GYRE
35%
Loosely correlated
+0.93%
More

RVPH and

Correlation & Price change

A.I.dvisor tells us that RVPH and GYRE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RVPH and GYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RVPH
1D Price
Change %
RVPH100%
+4.32%
GYRE - RVPH
30%
Poorly correlated
-0.76%
CLDX - RVPH
28%
Poorly correlated
+0.77%
CDIO - RVPH
26%
Poorly correlated
+13.69%
TSHA - RVPH
26%
Poorly correlated
N/A
AFMD - RVPH
25%
Poorly correlated
+15.54%
More